Comparison of the Effects Between Bevacizumab and Mitomycin C on the Survival of Fibroblasts.
10.3341/jkos.2011.52.3.345
- Author:
Sin Hoo KIM
1
;
Jae Woo KIM
Author Information
1. Department of Ophthalmology, Catholic University of Daegu College of Medicine, Daegu, Korea. jwkim@cu.ac.kr
- Publication Type:Original Article
- Keywords:
Antiproliferation;
Bevacizumab;
Fibroblast;
Mitomycin C
- MeSH:
Antibodies, Monoclonal, Humanized;
Fibroblasts;
Humans;
Mitomycin;
Nitric Oxide;
Tenon Capsule;
Vascular Endothelial Growth Factor A;
Bevacizumab
- From:Journal of the Korean Ophthalmological Society
2011;52(3):345-349
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To compare the antiproliferative effects between bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), and mitomycin C in human Tenon's capsule fibroblasts. METHODS: Primarily cultured human Tenon's capsule fibroblasts were exposed to 0, 25, 50, 100, and 200 microg/ml bevacizumab and mitomycin C, and incubated for 5 days. Cellular survival and production of nitric oxide were assessed by MTT assay and Griess assay, respectively. RESULTS: Bevacizumab showed antiproliferative effects only at high concentrations (200 microg/ml) and revealed much less effect on the cellular survival compared to mitomycin C. In addition, bevacizumab did not affect the production of nitric oxide. CONCLUSIONS: The antiproliferative effect of bevacizumab is much lower than mitomycin C in human Tenon's capsule fibroblasts.
